Acetazolamide‐associated aplastic anaemia

Keisu, Marianne; Wiholm, Bengt‐Erik; A, Ost; Mortimer, Örjan

doi:10.1111/j.1365-2796.1990.tb00290.x

Cited by 45 publications

(19 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is the case with the risk of aplastic anaemia during acetazolamide treatment, in which the background incidence of the condition under study is low and so is the number of exposed patients in the population [16,17].…”

Section: Referencesmentioning

confidence: 99%

Comparing risk estimates of sulphonamide-induced agranulocytosis from the Swedish Drug Monitoring System and a case-control study

Keisu

Ekman

Wiholm

1992

Eur J Clin Pharmacol

Self Cite

View full text Add to dashboard Cite

A comparison has been made of risk estimates for agranulocytosis connected with sulphasalazine and trimethoprim-sulphamethoxazole (T-SM) therapy calculated from data in the Swedish Drug Monitoring System ("spontaneous" reports, sales and prescription information) and a population based case-control study (the IAAAS). The relative risk for agranulocytosis during sulphasalazine treatment was calculated to be 107 and 123 by the spontaneous reporting system and the case-control study, respectively. The corresponding excess risk in both systems was 1.8. For T-SM the relative risk was 17 in the spontaneous reporting system and 12 in the case-control study, while the excess risk calculated for 3 days of treatment was 0.9 in the spontaneous reporting system, and 1.6 for 3 or more days of treatment in the case-control study. It is concluded that the Swedish Drug Monitoring System gives an appropriate estimate of the risk of developing agranulocytosis in association with the two drugs studied.

show abstract

Section: Referencesmentioning

confidence: 99%

Comparing risk estimates of sulphonamide-induced agranulocytosis from the Swedish Drug Monitoring System and a case-control study

Keisu

Ekman

Wiholm

1992

Eur J Clin Pharmacol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Not visualized by x-ray crystallography of canine parvovirus were the 40 most N-terminal residues of the major capsid protein or the unique region of VP1 (33). The N terminus of VP1 may reach the capsid surface through a cylindrical tunnel of -8 A diameter at each of the fivefold axes of the icosahedron; in canine parvovirus, aa 38 was sited near the interior of the capsid at the fivefold axis (7).…”

Section: Discussionmentioning

confidence: 99%

Parvovirus particles as platforms for protein presentation.

Miyamura

Kajigaya

Momoeda

et al. 1994

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Empty capsids of the human pathogenic parvovirus B19 can be produced in a baculovirus system. B19 capids are composed mainly of major capsid protein (VP2) and a small amount of minor capsid protein (VP1); VP1 is identical to VP2 but contains an additional 227-aa N-terminal region ("unique" region). A portion of that region of VP1 is external to the capsid, and VP1 is not required for capsid formation. We substituted the unique region with a sequence encoding the 147 aa of hen egg white lysozyme (HEL) and constructed recombinant baculoviruses with variable amounts of retained VP1 sequence joined to the VP2 backbone. After cotrandection with VP2 baculovirus and expression in insect cells, capsids were purified by density simentaion. Purified recombinant capsids contained HEL. External presentation of HEL was demonstrated by immunoprecipitation, ELISA, and immune electron microscopy using anti-lysozyme mnnodonal antibodies or specific rabbit antisera. Empty particles showed enzymatic activity in a micrococcal cell wall digon amay.Rabbits inoculated with capsids made antibodies to HEL.Intact heterologous protein can be incorporated in B19 particles and presented on the capsid surface, properties that may be useful in vaccine development, cell targetig, and gene therapy.

show abstract

“…Fortunately, the incidence of aplastic anemia associated with oral CAIs is low. Keisu et al in 1990 298 estimated it is "approximately one in 18,000 patient years." Patients present with a constellation of symptoms, including fever, easily bruised skin, purpura, sore throat, paleness, nosebleeds, petechaie, and perhaps jaundice.…”

Section: Carbonic Anhydrase Inhibitorsmentioning

confidence: 97%

“…Patients present with a constellation of symptoms, including fever, easily bruised skin, purpura, sore throat, paleness, nosebleeds, petechaie, and perhaps jaundice. 298,299 The use of blood tests to monitor for blood dyscrasias is controversial. 300 In an editorial in 2000, 301 Fraunfelder and Bagby weigh the pros and cons of doing routine, periodic blood tests on patients taking oral CAIs, hopefully to catch early any abnormalities and to be able to cease the drug and treat the reversible cases.…”

Section: Carbonic Anhydrase Inhibitorsmentioning

confidence: 99%

Medications Used to Treat Glaucoma

Schacknow

Samples

2010

The Glaucoma Book

View full text Add to dashboard Cite

ConclusionOptimal therapy for glaucoma would involve IOP control throughout the 24-h period. However, not all therapies are equally efficacious at all times of the day and night. Understanding of the mechanisms of action of different therapies, along with the knowledge of the circadian changes in aqueous humor dynamics, allows us to predict the therapies that will provide the most consistent IOP reduction. As well, understanding of aqueous humor dynamics may help in the development of future therapies with consistent 24-h IOP control. Bibliography

show abstract

Acetazolamide‐associated aplastic anaemia

Cited by 45 publications

References 10 publications

Comparing risk estimates of sulphonamide-induced agranulocytosis from the Swedish Drug Monitoring System and a case-control study

Comparing risk estimates of sulphonamide-induced agranulocytosis from the Swedish Drug Monitoring System and a case-control study

Parvovirus particles as platforms for protein presentation.

Medications Used to Treat Glaucoma

Contact Info

Product

Resources

About